Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q3 FY20 results · Oct–Dec 2019
Ajanta Pharma reported revenue from operations of ₹651.21 crore (up 34.2% from Q3 FY19) and net profit of ₹107.55 crore (up 60.8% from Q3 FY19) for Q3 FY20 (Oct–Dec 2019), on a consolidated basis.
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 651.21 | 485.11 | +34.2% | 642.76 | +1.3% |
| Other income | 14.64 | 4.41 | +232.0% | 13.22 | +10.7% |
| Total income | 665.85 | 489.52 | +36.0% | 655.98 | +1.5% |
| Profit before tax | 175.10 | 92.96 | +88.4% | 161.56 | +8.4% |
| Net profit for the period | 107.55 | 66.90 | +60.8% | 116.36 | −7.6% |
| EPS, basic (₹) | 12.33 | 7.60 | +62.2% | 13.34 | −7.5% |
| Net margin (%) | 16.5 | 13.8 | 18.1 |
| Item | Q3 FY20 | Q3 FY19 | YoY | Q2 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 530.55 | 451.85 | +17.4% | 559.45 | −5.2% |
| Other income | 51.17 | 12.97 | +294.5% | 39.31 | +30.2% |
| Total income | 581.72 | 464.82 | +25.1% | 598.76 | −2.8% |
| Profit before tax | 165.77 | 125.70 | +31.9% | 160.83 | +3.1% |
| Net profit for the period | 108.32 | 95.47 | +13.5% | 120.70 | −10.3% |
| EPS, basic (₹) | 12.41 | 10.85 | +14.4% | 13.83 | −10.3% |
| Net margin (%) | 20.4 | 21.1 | 21.6 |
Consolidated
- Filed with BSE
- 06 Feb 2020, 11:38 IST
- Board meeting
- 05 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 06 Feb 2020, 11:38 IST
- Board meeting
- 05 Feb 2020
- Period
- 01 Oct 2019 to 31 Dec 2019
- Review status
- Unaudited
- Source
- XBRL filing on BSE